Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
October 26, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week

VANCOUVER, British Columbia, Oct. 26, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
September 23, 2022 12:29 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and...
September 19, 2022 18:00 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
September 13, 2022 17:12 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
September 09, 2022 17:00 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

VANCOUVER, British Columbia, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
September 08, 2022 14:08 ET | Source: InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare...
August 23, 2022 17:00 ET | Source: InMed Pharmaceuticals Inc.

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
August 09, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Announces Changes to its Board of Directors

VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
July 25, 2022 07:30 ET | Source: InMed Pharmaceuticals Inc.

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right